COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia말레이시아에서 BNT162b2 백신을 접종한 의료 종사자의 COVID-19 획기적인 감염 및 체액성 면역 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] 95% CI affected age Anti-S1 Anti-spike antibody Antibody Response antibody titres association Asymptomatic Asymptomatic individuals blood sample Blood samples BNT162b2 booster vaccination breakthrough Breakthrough infection breakthrough infections collected COVID-19 COVID-19 infection delta variant detectable domain geometric mean geometric mean titre GMT HCWs healthcare healthcare worker Healthcare workers humoral humoral immune response Humoral immunity IgG IgG assay individual individuals Infection investigated Malaysia not different notable outcome Participants prospective cohort study Protein response significantly significantly higher Support symptomatic the antibody response vaccination Vaccine vaccine doses waned was measured [DOI] 10.1080/22221751.2022.2065936 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age Analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19Article Published on 2022-11-302022-11-15 Journal: Human vaccines & immunotherapeutics [Category] SARS, 진단, [키워드] adverse effect animal models antibody Antibody titer BALB/c mice changes in class COVID-19 COVID-19 vaccine demonstrated did not produce ELISA ENhance enzyme-linked immunosorbent ferrets Gender general condition GMT group growth hamster hamsters Health histology immune response immunization immunogenicity Inactivated vaccine injection internal organ Kazakhstan lowest microneutralization MNA nontoxic preclinical trials rhesus macaque Safety significant difference statistically significant Toxicity Vaccine were assessed [DOI] 10.1080/21645515.2022.2087412 PMC 바로가기
Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of Clinical Virology [Category] SARS, 변종, 진단, 치료기술, [키워드] antibody Antibody neutralization Antibody titre B.1.1.529 BNT162b2 booster Breakthrough infection convalescent CoronaVac COVID-19 detectable dose elicited geometric GMT Immune escape individual Infection less natural infection neutralization neutralizing antibody Neutralizing antibody response of BNT162b2 omicron Omicron, Neutralization plaque reduction neutralization PRNT reduction relative SARS-CoV-2 susceptible Transmissibility vaccinated individual vaccination Vaccine Vaccines virus viruses VoC wild- type WT virus [DOI] 10.1016/j.jcv.2022.105273 PMC 바로가기
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant심장 이식 수혜자를 대상으로 6개월 동안 세 번째 BNT162B2 코로나19 백신에 대한 세포 및 체액 반응의 동역학 - 오미크론 변종에 대한 영향Article Published on 2022-10-012022-11-15 Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), SARS, 백일해, 변종, 진단, 파상풍, [키워드] accelerate applied BNT162b2 BNT162b2 vaccine Bonferroni method cellular continuous variable COVID-19 vaccine declined dichotomous variables dose effective elicited geometric mean titer GMT Heart transplantation Humoral response immune response implication Kinetics Kruskal-Wallis test mRNA vaccines neutralization Neutralizing Neutralizing activity omicron Omicron variant percentage recipient remained SARS-CoV-2-specificT-cell sera serum sustained T-cell Response transmissible variant vaccination variant wild-type wild-type virus [DOI] 10.1016/j.healun.2022.05.014 PMC 바로가기
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysisArticle Published on 2022-09-132022-11-15 Journal: Frontiers in Immunology [Category] 변종, 진단, [키워드] 95% confidence interval Adults adverse event AEs analyzed booster caused Cochrane Library control group control groups Controlled trial coronavirus disease Coverage COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines DNA vaccines dose Efficacy eligible Factor Factors Fever follow-up period geometric mean titer GMT Health highest immunogenicity inactivated incidence Increased Local Meta-analysis meta-regression analysis mRNA vaccine Neutralizing antibodies Older older adult Older adults outcome Pain provided random-effect Randomized controlled trial randomized controlled trials (RCTs) Registered required Research risk Safety searched seroconversion rate severe disease significantly increased SMD standardized mean difference Strains Surveillance susceptible systematic review systemic AEs Universal vaccination Vaccine variant Web of Science [DOI] 10.3389/fimmu.2022.965971 PMC 바로가기
Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccinationArticle Published on 2022-09-092022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] age analyzed anti-SARS-CoV-2 antibody BBIBP-CorV blood sample booster dose booster doses change Chi-square China convalescent convalescent sera CoronaVac COVID-19 COVID-19 vaccine cross-sectional Cytopathic effect dose enrolled evaluated Factor Factors FIVE geometric mean concentration geometric mean titer GMC GMT immune immune persistence immunogenicity Immunoglobulin inactivated individual Influencing factors linear models Logistic regression NAb neutralizing antibody NIBSC nine number ranged real-world data recipient recipients sample sizes SARS-CoV-2 SARS-CoV-2 strain seropositive Seropositivity Sex Standard subject understanding vaccination Vaccine Vaccines Vero Cell were measured WHO Zhejiang [DOI] 10.3389/fimmu.2022.967051 PMC 바로가기
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in JapanArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott acute respiratory syndrome Adults age anti-RBD Anti-RBD antibody anti-RBD antibody response anti-receptor-binding domain anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 S antibody Antibody Response Antibody titer Architect Architect SARS-CoV-2 IgG II Quant assays blood sample BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine collected comparable Coronavirus-2 correlation dose Elecsy Elecsys Elecsys Anti-SARS-CoV-2 S evaluated first vaccination geometric GMT GMT ratio GMTs healthcare healthy immunoassay immunoassays Japan Kinetics mRNA vaccine no significant difference Older age Participants prospective cohort study RBD Roche Diagnostics SARS-CoV-2 SARS-CoV-2 IgG second vaccination Sex significantly lower Spearman vaccination were measured [DOI] 10.1016/j.vaccine.2022.08.018 PMC 바로가기